Developing cancer-specific, H2O2-activatable, and O2-evolving micelles encapsulating near-IR photosensitizers for phototherapy of breast cancer

开发癌症特异性、H2O2 可激活和 O2 释放的胶束,封装近红外光敏剂用于乳腺癌光疗

基本信息

  • 批准号:
    10753659
  • 负责人:
  • 金额:
    $ 43.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-02-01 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Phototherapy, including photodynamic therapy (PDT) and photothermal therapy (PTT), is an alternative cancer treatment modality based on the ability of photosensitizers (PSs) to convert photon energy into reactive oxygen species (ROS, i.e. singlet oxygen, superoxide anion, hydroxyl free radical, etc.) or heat. PDT/PTT treatment has special selectivity because the treatment only becomes effective when the PS is activated by light. PDT/PTT has the advantages of noninvasiveness, little or no scarring due to the fast healing process, and being able to treat the patients in an outpatient setting. However, the drawbacks of currently available porphyrin-based PSs, such as the inability to be activated by near-IR (NIR) light, low ROS generation efficiency in hypoxic solid tumors, low selectivity for cancerous tissue, and long-lasting cutaneous photosensitivity, have limited the application of PDT to superficial tumors. To solve these problems, we plan to apply our newly developed strong NIR-absorbing PS BODIPY-Ir to PDT/PTT by encapsulating it into cancer specific targeting, H2O2-activatable, and O2-evolving micelles to efficiently produce ROS in hypoxia. We hypothesize that the proposed micelles loaded with the NIR-absorbing Ir(III) PS can specifically target tumors and be activated by H2O2 and efficiently generate more toxic forms of ROS than H2O2 to improve the PDT efficiency under hypoxia. Three Specific Aims will be pursued in this project - Aim 1: To encapsulate our NIR PS BODIPY-Ir into H2O2-activatable and O2-evolving micelles for cancer-specific targeting and efficient ROS generation in hypoxia; and to evaluate the micelle encapsulation, release, ROS generation in hypoxia, and photothermal conversion efficiency in PBS solutions; Aim 2: To evaluate the in vitro inhibition of growth, migration and invasion of breast cancer cells by new-generation BODIPY-Ir micelle PDT/PTT; Aim 3: To evaluate the in vivo therapeutic outcomes of inhibiting tumor growth and metastasis following new-generation BODIPY-Ir micelle PDT/PTT treatment. Breast cancer cell lines, MDA MB-231 and 4T1, and tumor model Balb/c mice/4T1 will be used to test our hypothesis in vitro and in vivo, respectively. Our long-term objective is to advance the PDT/PTT modality for a more effective and much safer cancer therapy of triple-negative breast cancer. Twelve undergraduate students including Native American students will be trained in this project. The participating students will be involved in all scientific aspects of this project, including PS synthesis, micelle formation and characterization, photophysical studies, and in vitro and in vivo photobiological studies, from which they will be extensively trained on various biomaterials and biomedical research lab skills. These students will also be trained on literature usage, data collection and analysis, scientific writing and presentation, time management, and communication / interpersonal skills. More importantly, our training will help students becoming independent researchers who are capable of critical thinking and solving challenging health-related scientific problems in a creative and effective manner.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wenfang Sun其他文献

Wenfang Sun的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

5'-tRF-GlyGCC通过SRSF1调控RNA可变剪切促三阴性乳腺癌作用机制及干预策略
  • 批准号:
    82372743
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
脊髓电刺激活化Na(V)1.1阳性GABA神经元持续缓解癌痛
  • 批准号:
    82371223
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
丁酸梭菌代谢物(如丁酸、苯乳酸)通过MYC-TYMS信号轴影响结直肠癌化疗敏感性的效应及其机制研究
  • 批准号:
    82373139
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
均相液相生物芯片检测系统的构建及其在癌症早期诊断上的应用
  • 批准号:
    82372089
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
靶向PARylation介导的DNA损伤修复途径在恶性肿瘤治疗中的作用与分子机制研究
  • 批准号:
    82373145
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
基于密度泛函理论金原子簇放射性药物设计、制备及其在肺癌诊疗中的应用研究
  • 批准号:
    82371997
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
BRPF1 m6A修饰异常通过重塑BCAT1超级增强子介导Setd2缺陷型肾癌支链氨基酸代谢成瘾的机制研究
  • 批准号:
    82372724
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
基于影像代谢重塑可视化的延胡索酸水合酶缺陷型肾癌危险性分层模型的研究
  • 批准号:
    82371912
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
DRAM1与VAMP8相互作用调控自噬融合以促进肺癌细胞血管外渗的分子机制研究
  • 批准号:
    32000523
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
SAMMSON-CARF-p53信号轴调控黑色素瘤适应性耐药的机制研究
  • 批准号:
    32000541
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Collaborative research: Developing cancer-specific targeting near-IR photosensitizers for in vitro theranostic photodynamic therapy and photothermal therapy
合作研究:开发用于体外治疗诊断光动力疗法和光热疗法的癌症特异性靶向近红外光敏剂
  • 批准号:
    2317606
  • 财政年份:
    2023
  • 资助金额:
    $ 43.19万
  • 项目类别:
    Continuing Grant
Developing diagnostics of patient-specific cancer risk and early-stage tumorigenesis
开发患者特异性癌症风险和早期肿瘤发生的诊断方法
  • 批准号:
    478999
  • 财政年份:
    2023
  • 资助金额:
    $ 43.19万
  • 项目类别:
    Operating Grants
Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer Immunotherapy
阐明癌症相关 FGL1 在肿瘤免疫中的作用并开发 FGL1 引导的抗 LAG-3 癌症免疫疗法
  • 批准号:
    10504399
  • 财政年份:
    2022
  • 资助金额:
    $ 43.19万
  • 项目类别:
S.E.N.D.: Developing a web-based, interactive guide to enhance patient-clinician electronic communication by focusing on specificity, expressing concerns, need, and directness
S.E.N.D.:开发基于网络的交互式指南,通过关注特异性、表达顾虑、需求和直接性来增强患者与临床医生的电子通信
  • 批准号:
    10513009
  • 财政年份:
    2022
  • 资助金额:
    $ 43.19万
  • 项目类别:
Developing a genetic tag for in vivo protein regulation using PROTACs with companion PET imaging
使用 PROTAC 和伴随 PET 成像开发用于体内蛋白质调节的遗传标签
  • 批准号:
    10535045
  • 财政年份:
    2022
  • 资助金额:
    $ 43.19万
  • 项目类别:
Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer Immunotherapy
阐明癌症相关 FGL1 在肿瘤免疫中的作用并开发 FGL1 引导的抗 LAG-3 癌症免疫疗法
  • 批准号:
    10663382
  • 财政年份:
    2022
  • 资助金额:
    $ 43.19万
  • 项目类别:
S.E.N.D.: Developing a web-based, interactive guide to enhance patient-clinician electronic communication by focusing on specificity, expressing concerns, need, and directness
S.E.N.D.:开发基于网络的交互式指南,通过关注特异性、表达顾虑、需求和直接性来增强患者与临床医生的电子通信
  • 批准号:
    10683245
  • 财政年份:
    2022
  • 资助金额:
    $ 43.19万
  • 项目类别:
Developing novel bispecific antibodies for cancer treatment
开发用于癌症治疗的新型双特异性抗体
  • 批准号:
    10441600
  • 财政年份:
    2021
  • 资助金额:
    $ 43.19万
  • 项目类别:
Developing Methods for Precise, Safe and Target-location Specific Histotripsy of Liver Tumors
开发精确、安全、靶向定位的肝脏肿瘤特异性组织切片方法
  • 批准号:
    10493362
  • 财政年份:
    2021
  • 资助金额:
    $ 43.19万
  • 项目类别:
Developing novel bispecific antibodies for cancer treatment
开发用于癌症治疗的新型双特异性抗体
  • 批准号:
    10276280
  • 财政年份:
    2021
  • 资助金额:
    $ 43.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了